Paying For GLP-1s: If Medicare Starts, Will Other Insurers Follow Suit? (Medscape)

A proposed rule could dramatically expand Medicare and Medicaid coverage for GLP-1 receptor agonists like Wegovy and Zepbound, making these costly weight loss drugs more accessible. If finalized, the rule could grant 3.4 million Medicare and 4 million Medicaid recipients access to obesity medications, pressuring private insurers to follow suit—just as they did after Medicare covered bariatric surgery in 2006.